Early Phase/Multi Tumor Trials
Below is a list of early phase clinical trials that may recruit from many different cancer diseases. To find out more about a particular clinical trial, click on the “study Information link” for the trial. Once you are in the study specific page, there is a link to contact the study team.
STUDY26821
A Phase 1, First-in-Human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors
To determine the MonoRD and/or MTD (or highest cleared DL) of JZP898 as well as the CombiRD of JZP898 in combination with pembrolizumab. To characterize the safety and tolerability profile of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab.
Study InformationSTUDY26995
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors
To determine the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. To determine the recommended dose(s) for expansion (RDE)s of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. The RDE may be the maximum tolerated dose (MTD) or a biologically active dose below the MTD.
Study InformationSTUDY28741
A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants with Prostate Cancer
To assess safety and tolerability of JANX014. To determine the maximum tolerated dose regimen (MTD-R) and/or maximally administered dose (MAD). To assess potential Phase 2 doses and determine a recommended Phase 2 dose regimen (RP2D-R).
Study InformationSTUDY29471
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
Determine a recommended Phase 2 dose (Rp2D) and schedule of KTX-1001 and/or the maximum tolerated dose (MTD) and schedule of KTX-1001.
Study Information